H. Lundbeck A/S - Articles and news items

SMC accepts five new medicines for use in NHS Scotland

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib…

FDA issues complete response letter for Brintellix sNDA

Industry news / 29 March 2016 / Victoria White

The FDA have issued a CRL to include new data in the clinical trials section of the US label of Brintellix for treating aspects of cognitive dysfunction in MDD…

Lundbeck starts Lu AF35700 Phase III programme in treatment-resistant schizophrenia

Industry news / 14 March 2016 / Victoria White

The Phase III programme will consist of two pivotal trials. Two doses of Lu AF35700 will be tested in patients with treatment resistant schizophrenia…

PDAC supports effectiveness of Brintellix in treating cognitive dysfunction in MDD

Industry news / 4 February 2016 / Victoria White

The FDA Advisory Committee reviewed data from studies designed to assess the effect of Brintellix on cognitive dysfunction in adult patients with MDD…

New data released from QUALIFY study of aripiprazole once-monthly

Industry news / 24 June 2015 / Victoria White

Otsuka and Lundbeck have announced newly released subgroup analysis of data from the QUALIFY study of Abilify Maintena (aripiprazole once-monthly)…

Lundbeck logo

European CHMP issues positive opinion for a label update of Lundbeck’s Brintellix® (vortioxetine)

Industry news / 5 March 2015 / H. Lundbeck A/S

Lundbeck today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for a Type-II Variation related to the update of the European summary of the product characteristics (SmPC) for Brintellix…

H. Lundbeck A/S Logo 60x60

Otsuka and Lundbeck´s brexpiprazole demonstrates statistically significant effects in New Phase III Studies in adult patients with schizophrenia

Industry news / 11 December 2014 / H. Lundbeck A/S

… presented at the American College of Neuropsychopharmacology annual meeting.

H. Lundbeck A/S Logo 60x60

Brintellix is launched as the first new antidepressant drug in five years in Denmark

Industry news / 16 September 2014 / Lundbeck

…and will be introduced in several other European and International Markets during 2014 and 2015.

H. Lundbeck A/S Logo 60x60

Brintellix® demonstrated a statistically significantly superior improvement compared to escitalopram in improving sexual functioning in well treated patients suffering from depression and experiencing treatment-emergent sexual dysfunction

Industry news / 19 June 2014 / H. Lundbeck A/S

Lundbeck will present results about sexual functioning from a head-to-head study of Brintellix® (vortioxetine) vs. escitalopram in patients with well treated Major Depressive Disorder…

H. Lundbeck A/S Logo 60x60

Lundbeck to present new Brintellix® data at the Annual Society of Clinical Psychopharmacology (ASCP) Meeting

Industry news / 29 May 2014 / H. Lundbeck A/S

Data highlights safety and efficacy profile of Brintellix, including difficult to treat patients and special patient populations…

H. Lundbeck A/S Logo 60x60

Lundbeck part of major advances in the understanding of Parkinson’s disease

Industry news / 20 May 2014 / Lundbeck

H. Lundbeck A/S is involved in new research on Parkinson’s disease, which may be the first step towards a new and significantly improved treatment of the debilitating and devastating disease…

H. Lundbeck A/S Logo 60x60

Lundbeck receives grant from The Michael J. Fox Foundation for biological markers identification in Parkinson’s disease

Industry news / 6 May 2014 / H. Lundbeck A/S

H. Lundbeck A/S has once again received support and recognition for its research on Parkinson’s disease through a grant from The Michael J. Fox Foundation for Parkinson’s Research…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...